Literature DB >> 10795095

[MRI spectroscopy, T2 relaxometry, and postoperative prognosis in cryptogenic temporal lobe epilepsy].

H Stefan1, E Pauli, K E Eberhardt, I Schäfer, P Hopp, W J Huk.   

Abstract

The preoperative localization of pharmaco-resistant focal epilepsies before surgery and the prognosis concerning seizure outcome are both of importance. In addition to conventional MRI diagnostics for the detection of small epileptogenic lesions, proton magnetic resonance spectroscopic imaging (HMR spectroscopy) can be useful for assessing the bilaterality of pathological changes in cryptogenic temporal lobe epilepsies. The technique and findings of HMR spectroscopy are reported in patients with cryptogenic temporal lobe epilepsies. The findings indicate that chemical shift imaging (CSI) investigations of the ipsilateral and contralateral hemispheres provide important information for the prediction of seizure outcome after epilepsy surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10795095     DOI: 10.1007/s001150050558

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

Review 1.  [(1)H MR spectroscopy. Methods and applications in diagnosis and assessment of surgical and conservative treatment strategies in epilepsies].

Authors:  T Hammen; H Stefan
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 2.  Identification of common predictors of surgical outcomes for epilepsy surgery.

Authors:  Jing Zhang; Weifang Liu; Hui Chen; Hong Xia; Zhen Zhou; Shanshan Mei; Qingzhu Liu; Yunlin Li
Journal:  Neuropsychiatr Dis Treat       Date:  2013-11-06       Impact factor: 2.570

3.  Identifying the affected hemisphere with a multimodal approach in MRI-positive or negative, unilateral or bilateral temporal lobe epilepsy.

Authors:  Jing Zhang; Qingzhu Liu; Shanshan Mei; Xiaoming Zhang; Weifang Liu; Hui Chen; Hong Xia; Zhen Zhou; Xiaofei Wang; Yunlin Li
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-07       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.